IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1251.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 24-Feb-2017
ecancermedicalscience
The potential consequences for cancer care and cancer research of Brexit
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.

Contact: Karen Watts
karen@ecancer.org
ecancermedicalscience

Public Release: 24-Feb-2017
Cancer Discovery
Molecular 'on switch' could point to treatments for pediatric brain tumor
Massachusetts General Hospital researchers have identified a mechanism that controls the expression of genes regulating the growth of the most aggressive form of medulloblastoma, the most common pediatric brain tumor.
A Kids' Brain Tumor Cure Foundation, Pediatric Low Grade Astrocytoma Foundation

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 24-Feb-2017
Tissue Engineering: Part C
Tissue-engineered model developed to study bone-invading tumor
Researchers have used tissue engineering to create models for studying the bone-destroying activity of tumors such as the aggressive pediatric cancer Ewing's sarcoma.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2250
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 24-Feb-2017
Science Immunology
Novel 'barcode' tracking of T cells in immunotherapy patients identifies likely cancer-
A new discovery by researchers at the Fred Hutchinson Cancer Research Center in Seattle makes an important step in identifying which specific T cells within the diverse army of a person's immune system are best suited to fight cancer. The findings will be published Feb. 24 in Science Immunology.
Cancer Research Institute, Stand Up To Cancer

Contact: Molly McElroy
mwmcelro@fredhutch.org
206-667-6651
Fred Hutchinson Cancer Research Center

Public Release: 24-Feb-2017
Molecular Therapy
A novel DNA vaccine design improves chances of inducing anti-tumor immunity
Scientists at The Wistar Institute and Inovio Pharmaceuticals, Inc. have devised a novel DNA vaccine approach through molecular design to improve the immune responses elicited against one of the most important cancer antigen targets.
Inovio Pharmaceuticals, Inc. Basser Center for BRCA/Abramson Cancer CenterWeiner, W.W. Smith Charitable Trust Professorship for Cancer Research

Contact: Darien Sutton
dsutton@wistar.org
215-898-3988
The Wistar Institute

Public Release: 24-Feb-2017
Cell
New structural studies reveal workings of a molecular pump that ejects cancer drugs
Sometimes cells spit out things we don't want them to -- like medications. Researchers have determined the three-dimensional structure of a tiny pump that expels, among other things, chemotherapy agents. This new knowledge could lead to the design of more effective drugs.

Contact: Katherine Fenz
kfenz@rockefeller.edu
212-327-7913
Rockefeller University

Public Release: 24-Feb-2017
The American Society for Blood and Marrow Transplantation (ASBMT)
New antiviral drug cuts cytomegalovirus infection and improves survival in patients
In a significant advance in improving the safety of donor stem cell transplants, a major clinical trial led by researchers at Dana-Farber Cancer Institute has shown that a novel agent can protect against the most common viral infection that patients face after transplantation.

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-5665
Dana-Farber Cancer Institute

Public Release: 23-Feb-2017
Molecular Cell
Study reveals PGK1 enzyme as therapeutic target for deadliest brain cancer
Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma, an often fatal form of brain cancer, according to researchers at The University of Texas MD Anderson Cancer Center.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 23-Feb-2017
Clinical Cancer Research
PI3K/mTOR inhibitors may be effective against some uterine sarcomas
The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may respond to PI3K/mTOR inhibitors.
Prague's biobanking grant project, Swedish Labour Market Insurance and Swedish Medical Research Council, Western Norway Regional Health Authority (Helse Vest RHF), Norwegian Cancer Society, Norwegian Research Council

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research

Public Release: 23-Feb-2017
Journal of Experimental Medicine
Why is pancreatic cancer so hard to treat? Stroma provides new clues
Why are pancreatic tumors so resistant to treatment? One reason is that the 'wound'-like tissue that surrounds the tumors, called stroma, is so dense, likely preventing cancer-killing drugs from reaching the tumor. A team has now discovered heterogeneity in the fibroblast portion of the stroma, opening up the possibility of targeted treatment.
Cold Spring Harbor Cancer Center Support Grant, NIH/National Cancer Institute, The Lustgarten Foundation, Cold Spring Harbor Laboratory Association, National Institutes of Health

Contact: Peter Tarr
tarr@cshl.edu
516-367-5055
Cold Spring Harbor Laboratory

Public Release: 23-Feb-2017
Clinical Cancer Research
Anti-aging gene identified as a promising therapeutic target for older melanoma patients
Scientists at The Wistar Institute have shown that an anti-diabetic drug can inhibit the growth of melanoma in older patients by activating an anti-aging gene that in turn inhibits a protein involved in metastatic progression and resistance to targeted therapies for the disease.
Melanoma Research Foundation, American Cancer Society, Miriam and Sheldon Adelson Research Foundation, Ira Brind Associate Professorship

Contact: Darien Sutton
dsutton@wistar.org
215-898-3988
The Wistar Institute

Public Release: 23-Feb-2017
PLOS Computational Biology
Novel mutation may be linked to prostate cancer in African-American men
Researchers have identified a novel mutation that may be associated with prostate cancer in African-American men, according to a new study published in PLOS Computational Biology. Scientists have long known that a huge variety of DNA mutations can lead to cancer. Some proteins can repair DNA mutations, but when repair proteins are mutated themselves, cancer may arise. Knowing which mutations are linked to which cancer types helps scientists develop new targeted treatments and detection strategies.

Contact: G. Andrés Cisneros
andres@unt.edu
PLOS

Public Release: 23-Feb-2017
Genome Medicine
Broad cancer vaccine may be out of reach
The high level of genetic diversity between individual tumors suggests that if it were to be developed, a broad cancer vaccine would be unlikely to work for more than 0.3 percent of the population, according to new research published in the open access journal Genome Medicine.

Contact: Alanna Orpen
alanna.orpen@biomedcentral.com
020-319-22054
BioMed Central

Public Release: 23-Feb-2017
Molecular Cell
PERK protein opens line of communication between inside and outside of the cell
PERK is known to detect protein folding errors in the cell. Researchers at the Laboratory of Cell Death Research & Therapy at KU Leuven (University of Leuven, Belgium) have now revealed a hidden perk: the protein also coordinates the communication between the inside and the outside of the cell. These findings open up new avenues for further research into treatments for cancer, Alzheimer's, and diabetes.
Research Foundation Flanders, TrainERS/Horizon 2020, Innovation by Science and Technology

Contact: Patrizia Agostinis
patrizia.agostinis@kuleuven.be
KU Leuven

Public Release: 23-Feb-2017
Oncotarget
Gene mutations cause leukemia, but which ones?
Watanabe-Smith's research, published today in the journal Oncotarget, sought to better understand one 'typo' in a standard leukemia assay, or test. While studying cancer biology and completing his doctorate in the lab of Brian Druker, M.D., at the OHSU Knight Cancer Institute, Watanabe-Smith encountered a new problem: an issue with the model system itself.

Contact: Amanda Gibbs
gibbam@ohsu.edu
503-494-5640
Oregon Health & Science University

Public Release: 23-Feb-2017
International Journal of Cancer
Tumor protein could hold key to pancreatic cancer survival
A diagnosis of pancreatic cancer is often a death sentence because current chemotherapies have little impact on the disease.

Contact: Annie Rahilly
arahilly@unimelb.edu.au
61-390-355-380
University of Melbourne

Public Release: 23-Feb-2017
Nature Methods
New gene sequencing software could aid in early detection, treatment of cancer
A research team from the United States and Canada has developed and successfully tested new computational software that determines whether a human DNA sample includes an epigenetic add-on linked to cancer and other adverse health conditions.
Johns Hopkins University, Ontario Institute for Cancer Research, Ontario Ministry of Research, Innovation and Science

Contact: Phil Sneiderman
prs@jhu.edu
443-997-9907
Johns Hopkins University

Public Release: 23-Feb-2017
PAIN
Nicotinamide riboside (vitamin B3) prevents nerve pain caused by cancer drugs
A new study in rats suggests that nicotinamide riboside (NR), a form of vitamin B3, may be useful for treating or preventing nerve pain (neuropathy) caused by chemotherapy drugs. The findings by researchers at the University of Iowa were published recently in the Journal of the International Association for the Study of Pain (PAIN) and lay the groundwork for testing whether this nutritional supplement can reduce nerve pain in cancer patients receiving chemotherapy.
The Roy J. Carver Trust

Contact: Jennifer Brown
jennifer-l-brown@uiowa.edu
319-335-3590
University of Iowa Health Care

Public Release: 23-Feb-2017
Cell
Researchers uncover a role for HSP90 in gene-environment interactions in humans
Researchers at the Whitehead Institute have now uncovered a role for the protein-folding chaperone HSP90 in humans, not only as a modifier of the effects of mutations, but as a mediator of the impact of the environment on the function of mutant proteins. And these effects of HSP90 can alter the course of human diseases.
Fanconi Anemia Research Fund, US Department of Defense, Harold and Leila Y. Mathers Foundation, National Institutes of Health, European Molecular Biology Organization, Human Frontier Science Program

Contact: Nicole Giese Rura
rura@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research

Public Release: 23-Feb-2017
Human Gene Therapy
AAV gene delivery vectors and cancer -- The debate continues
Overwhelming evidence from the biomedical literature shows that adeno-associated virus 2 (AAV2), a viral vector often used to deliver therapeutic genes, is not associated with cancer and, in fact, may protect against cancer.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2250
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 22-Feb-2017
Nature
Nature study suggests new therapy for Gaucher disease
Scientists propose in Nature blocking a molecule that drives inflammation and organ damage in Gaucher, and maybe other lysosomal storage diseases, as a possible treatment with fewer risks and lower costs than current therapies. Reporting their data Feb. 22, the international research team conducted the study in mouse models of lysosomal storage disease and in cells from blood samples donated by people with Gaucher disease.

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center

Public Release: 22-Feb-2017
PLOS ONE
Incarceration linked to excess burden of cancer, new study finds
People who spend time in jails and prisons are more likely to develop certain types of cancer than the general population in Ontario, according to a study published today in the open-access journal PLOS ONE. They were also more than 50 percent more likely to die from cancer than the general population in Ontario, the study found.

Contact: Kelly O'Brien
obrienkel@smh.ca
416-864-5047
St. Michael's Hospital

Public Release: 22-Feb-2017
Nature
CAR T cells more powerful when built with CRISPR, MSK researchers find
Researchers from Memorial Sloan Kettering Cancer Center have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice.
Lake Road Foundation, Mr. William H. and Mrs. Alice Goodwin, Commonwealth Foundation for Cancer Research, Stand Up To Cancer, American Association for Cancer Research, Lymphoma and Leukemia Society, NYSTEM, NIH/National Cancer Institute

Contact: Caitlin Hool
hoolc@mskcc.org
Memorial Sloan Kettering Cancer Center

Public Release: 22-Feb-2017
Clinical Cancer Research
Measuring patients' muscles to predict chemotherapy side effects
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center report in the journal Clinical Cancer Research that measuring patients' muscle mass and quality could potentially help doctors better identify patients at high risk for toxic side effects that could require hospitalizations.

Contact: Laura Oleniacz
laura_oleniacz@med.unc.edu
919-445-4219
UNC Lineberger Comprehensive Cancer Center

Public Release: 22-Feb-2017
Cell Reports
Scientists identify chain reaction that shields breast cancer stem cells from chemotherapy
Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.
US Department of Defense, American Cancer Society

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine

Showing releases 1-25 out of 1251.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases

     

 

EurekAlert!